According to a new report, published by KBV research, The Global Anti-Obesity Drugs Market size is expected to reach $3.1 billion by 2029, rising at a market growth of 10.6% CAGR during the forecast period.
Over The Counter Drugs segment is showcasing a CAGR of 11.4% during (2023 - 2029). This is because these products reduce fat absorption, which is subsequently excreted from the body through the stool and are in accordance with OTC guidelines. This pharmaceutical product is commonly recommended for individuals who are obese and may also be suffering from comorbidities such as hypertension, hyperlipidemia, hyperglycemia, or cardiovascular ailments. These medications comprise two active ingredients, phentermine and topiramate. Phentermine's immediate-release formulation enhances food intake control by elevating norepinephrine levels in the body.
The Centrally Acting segment acquired maximum revenue share in the Global Anti-Obesity Drugs Market by Mechanism of Action in 2022 thereby, achieving a market value of $1.9 billion by 2029. This is due to the fact that centrally acting anti-obesity drugs are a class of medications that were initially developed based on phenylethylamine, which is the chemical backbone for noradrenaline and dopamine. Amphetamine and its derivatives are utilized as sympathomimetic stimulants in the business of regulating the signaling of reward and locomotor activity.
The Subcutaneous Route segment has shown the growth rate of 12.4% during (2023 - 2029). This is due to the safety profile of this route being comparatively higher than that of intravenous and intramuscular administration. The absorption rate is comparatively slower, making it an ideal option for achieving a prolonged effect. Self-administration is viable, as the injection does not require deep penetration. Thus, these benefits of this route of administration will surge the segment's growth.
The Hospital Pharmacies segment is leading the Global Anti-Obesity Drugs Market by Distribution Channel in 2022 thereby, achieving a market value of $1.4 billion by 2029. This is because the hospital pharmacy provides prescriptions from a trained professional, which is still required for the procurement of medicines. The hospital pharmacies have various types of drugs that are authorized by the government authorities, thereby leaving no doubt regarding the authenticity of the medications. Thus, the availability of a wide range of drugs and the prescription from highly trained healthcare experts is expected to boost the segment's growth.
The North America market dominated the Global Anti-Obesity Drugs Market by Region in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1.1 billion by 2029. The Europe market is exhibiting a CAGR of 10.4% during (2023 - 2029). Additionally, The Asia Pacific market would showcase a CAGR of 11.6% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/anti-obesity-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Vivus LLC, CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH) and KVK Tech, Inc.
By Drug Type
By Mechanism of Action
By Route Of Administration
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
